51774 Federal Register / Vol. 62, No. 192 / Friday, October 3, 1997 / Rules and Regulations

Executive Order 12866

This amendment does not meet the

criteria of a ‘‘significant regulatory

action’’ as described in E.O. 12866.

Drafting Information: The principal

author of this document was Keith B.

Rudich, Esq., Regulations Branch, Office

of Regulations and Rulings, U.S.

Customs Service. However, personnel

from other offices participated in its

development.

List of Subjects in 19 CFR Part 12

Customs duties and inspections,

Imports, Cultural property.

Amendment to the Regulations

Accordingly, Part 12 of the Customs

Regulations (19 CFR Part 12) is

amended as set forth below:

PART 12—[AMENDED]

1. The general authority and specific

authority citation for Part 12, in part,

continue to read as follows:

Authority: 5 U.S.C. 301, 19 U.S.C. 66, 1202

(General Note 20, Harmonized Tariff

Schedule of the United States (HTSUS)),

1624;

* * * * *

Sections 12.104 through 12.104i also

issued under 19 U.S.C. 2612;

* * * * *

§ 12.104 [Amended]

2. In § 12.104g, paragraph (a) the list

of agreements imposing import

restrictions on described articles of

cultural property of State Parties is

amended by adding Guatemala in

appropriate alphabetical order as

follows:

State Cultural property T.D. No.

* * * * * * *

Guatemala ................................................... Archaeological Material From Sites In The Peten Lowlands Of Guatemala, And Related Pre-Columbian Material From The Highlands And The Southern Coast of

Guatemala.

T.D. 97—81

* * * * * * *

3. In § 12.104(g), paragraph (b), the list

of emergency actions imposing import

restrictions on described articles of

cultural property of State parties is

amended by removing the entry for

‘‘Guatemala’’ in its entirety.

Approved: September 29, 1997.

Samuel H. Banks,

Acting Commissioner of Customs.

John P. Simpson,

Deputy Assistant Secretary of the Treasury.

[FR Doc. 97–26219 Filed 10–2–97; 8:45 am]

BILLING CODE 4820–02–P

DEPARTMENT OF THE TREASURY

Customs Service

19 CFR Part 24

[T.D. 97–45]

RIN 1515–AA57

Update of Ports Subject to the Harbor

Maintenance Fee; Corrections

AGENCY: Customs Service, Treasury.

ACTION: Interim regulations; corrections.

SUMMARY: This document corrects an

omission that was made in the interim

regulations document published in the

Federal Register on June 4, 1997, which

updated the list of ports that process

commercial vessels that transport cargo

that are subject to the Water Resources

Development Act of 1986.

DATES: This correction is effective

October 3, 1997.

FOR FURTHER INFORMATION CONTACT:

Patricia Barbare, Office of Finance, (202)

927–0034.

SUPPLEMENTARY INFORMATION:

Background

On June 4, 1997, Customs published

in the Federal Register (62 FR 30448)

interim regulations (T.D. 97–45) which

amended § 24.24 of the Customs

Regulations (19 CFR 24.24) to update

the list of ports that process commercial

vessels that transport cargo that are

subject to the Water Resources

Development Act of 1986. A correction

document to these interim regulations

was published in the Federal Register

(62 FR 45156) on August 26, 1997. Since

then, it has come to Customs’ attention

that the June 4 document contains

another error. The interim rule

document failed to list under the

Galveston Bay Ports the ports of

Galveston and Texas City and their port

codes: 5310 and 5306, respectively.

Accordingly, this document corrects

that omission.

Corrections to Publication

The document (FR Doc. 97–14409)

published in the Federal Register (62

FR 30448) on June 4, 1997, is corrected

as follows:

1. On page 30453, under the heading

for ‘‘Texas’’, in the fourth line, the

listing ‘‘Galveston Bay Ports* ’’ should

read as follows:

Port code, port name

and state

Port descriptions and

notations

Port code, port name

and state

Port descriptions and

notations

* * * * *

Texas

* * * * *

Galveston Bay Ports*

5310—Galveston .......

5306—Texas City ......

Includes Port Bolivar

and all points on

Galveston Bay in

Galveston County.

Movements between points within

this area are

intraport.

* * * * *

Dated: September 29, 1997.

Harold M. Singer,

Chief, Regulations Branch.

[FR Doc. 97–26218 Filed 10–2–97; 8:45 am]

BILLING CODE 4820–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

21 CFR Part 1308

[DEA No. 161F]

Schedules of Controlled Substances:

Excluded Veterinary Anabolic Steroid

Implant Products

AGENCY: Drug Enforcement

Administration, Department of Justice.

ACTION: Final rule.

SUMMARY: The interim rule (62 FR

29289, May 30, 1997) which identified

eight veterinary anabolic steroid

implant products as being excluded
Federal Register / Vol. 62, No. 192 / Friday, October 3, 1997 / Rules and Regulations 51775

from the Controlled Substances Act

(CSA) (21 U.S.C. 801 et seq.) is adopted

without change.

DATES: Effective Date: October 3, 1997.

FOR FURTHER INFORMATION CONTACT:

Frank L. Sapienza, Chief, Drug and

Chemical Evaluation Section, 202–307–

7183.

SUPPLEMENTARY INFORMATION: The

Acting Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration (DEA),

published in the Federal Register, an

interim rule which identified eight

products as being excluded veterinary

anabolic steroid implant products (62

FR 29289, May 30, 1997). Comments

were requested, none were received.

Therefore, pursuant to the authority

delegated to the Administrator of the

DEA pursuant to 21 U.S.C. 871(a) and

28 CFR 0.100 and redelegated to the

Deputy Assistant Administrator of the

Drug Enforcement Administration

Office of Diversion Control, pursuant to

28 CFR 0.104, appendix to subpart R,

section 7(g), the Deputy Assistant

Administrator of the Office of Diversion

Control hereby adopts as a final rule,

without change, the interim rule

amending the products which are

described in 21 CFR 1308.26 which was

published at 62 FR 29289 on May 30,

1997.

The veterinary anabolic steroid

implant products which are described

in 21 CFR 1308.26 are excluded from

application of the CSA in relation to

their production, distribution, and use

in animals only. If any person

distributes, dispenses or otherwise

diverts these products to use in humans,

he/she shall be deemed to have

distributed a Schedule III controlled

substance and may be prosecuted for

CSA violations. The veterinary anabolic

steroid implants products which are

excluded from application of the CSA

are as follows:

EXCLUDED VETERINARY ANABOLIC STEROID IMPLANT PRODUCTS

Trade name Company NDC or DIN

No. Delivery system Ingredients Quantity

Component E–H Vetlife, Inc., Norcross, GA 021641–002 20 implant belt, 8 pellets/

implant.

Testosterone propionate ......

Estradiol benzoate ...............

200 mg/implant

(25 mg/pellet)

20 mg/implant

(2.5 mg/pellet)

Component E–H Elanco, Scarborough, ON 01968327 20 implant belt, 8 pellets/

implant.

Testosterone propionate ......

Estradiol benzoate ...............

200 mg/implant

(25 mg/pellet)

20 mg/implant

(2.5 mg/pellet)

Component TE–S VetLife, Inc., Norcross,

GA.

021641–004 20 implant belt, 6 pellets/

implant.

Trenbolone acetate ..............

Estradiol ...............................

120 mg/implant

(20 mg/pellet)

24 mg/implant

(4 mg/pellet)

Component T–H VetLife, Inc., Norcross,

GA.

021641–006 20 implant belt, 10 pellets/implant.Trenbolone acetate .............. 200 mg/implant

(20 mg/pellet)

Component T–S VetLife, Inc., Norcross,

GA.

021641–005 20 implant belt, 7 pellets/

implant.

Trenbolone acetate .............. 140 mg/implant

(20 mg/pellet)

F–TO .................. Animal Health, Upjohn

International, Kalamazoo, MI.

00093351 20 implant cartridge belt,

8 pellets/implant.

Testosterone propionate ......

Oestradiol benzoate .............

200 mg/implant

(25 mg/pellet)

20 mg/implant

(2.5 mg/pellet)

Finaplix-H ........... Hoechst Roussel Vet,

Somerville, NJ.

12799–807–10 10 implant cartridge, 10

pellets/implant.

Trenbolone acetate .............. 200 mg/implant

(20 mg/pellet)

Finaplix-S ........... Hoechst Roussel Vet,

Somerville, NJ.

12799–807–07 10 implant cartridge, 7

pellets/implant.

Trenbolone acetate .............. 140 mg/implant

(20 mg/pellet)

Heifer-oid ............ Anchor Division,

Boehringer Ingelheim,

St. Joseph, MO.

.......................... Single & 20 implant cartridge belts, 8 pellets/

implant.

Testosterone propionate ......

Estradiol benzoate ...............

200 mg/implant

(25 mg/pellet)

20 mg/implant

(2.5 mg/pellet)

Heifer-oid ............ Bio-Ceutic Division,

Boehringer Ingelheim,

St. Joseph, MO.

.......................... 20 implant cartridge belt,

8 pellets/implant.

Testosterone propionate ......

Estradiol benzoate ...............

200 mg/implant

(25 mg/pellet)

20 mg/implant

(2.5 mg/pellet)

Heifer-oid ............ Ivy Laboratories, Inc.,

Overland Park, KS.

.......................... Single & 20 implant cartridge belts, 8 pellets/

implant.

Testosterone propionate ......

Estradiol benzoate ...............

200 mg/implant

(25 mg/pellet)

20 mg/implant

(2.5 mg/pellet)

Implus-H ............. The Upjohn Co., Kalamazoo, MI.0009–0434–01 20 implant cartridge belt,

8 pellets/implant.

Testosterone propionate ......

Estradiol benzoate ...............

200 mg/implant

(25 mg/pellet)

20 mg/implant

(2.5 mg/pellet)

Implus-H ............. Upjohn Co., Animal

Health Div.,

Orangeville, ON.

06–0434–01

01968327

20 implant cartridge belt,

8 pellets/implant.

Testosterone propionate ......

Estradiol benzoate ...............

200 mg/implant

(25 mg/pellet)

20 mg/implant

(2.5 mg/pellet)

Revalor-G ........... Hoechst Roussel Vet,

Somerville, NJ.

12799–811 10 implant cartridge 2 pellets/implant.Trenbolone acetate ..............

Estradiol ...............................

40 mg/implant

(20 mg/pellet)

4 mg/implant

(2 mg/pellet)
51776 Federal Register / Vol. 62, No. 192 / Friday, October 3, 1997 / Rules and Regulations

EXCLUDED VETERINARY ANABOLIC STEROID IMPLANT PRODUCTS—Continued

Trade name Company NDC or DIN

No. Delivery system Ingredients Quantity

Revalor-H ........... Hoechst Roussel Vet,

Somerville, NJ.

12799–810 10 implant cartridge, 7

pellets/implant.

Trenbolone acetate ..............

Estradiol ...............................

140 mg/implant

(20 mg/pellet)

14 mg/implant

(2 mg/pellet)

Revalor-S ........... Hoechst Roussel Vet,

Somerville, NJ.

12799–809 10 implant cartridge, 6

pellets/implant.

Trenbolone acetate ..............

Estradiol ...............................

120 mg/implant

(20 mg/pellet)

24 mg/implant

4 mg/pellet)

Synovex H .......... Fort Dodge Labs, Fort

Dodge, IA.

0856–3901 10 implant clip, 8 pellets/

implant.

Testosterone propionate ......

Estradiol benzoate ...............

200 mg/implant

(25 mg/pellet)

20 mg/implant

(2.5 mg/pellet)

Synovex H .......... Syntex Laboratories, Palo

Alto, CA.

.......................... 10 implant clip, 8 pellets/

implant.

Testosterone propionate ......

Estradiol benzoate ...............

200 mg/implant

(25 mg/pellet)

20 mg/implant

(2.5 mg/pellet)

Synovex Plus ..... Fort Dodge Labs, Fort

Dodge, IA.

0856–3904 10 implant clip, 8 pellets/

implant.

Trenbolone acetate ..............

Estradiol ...............................

200 mg/implant

(25 mg/pellet)

28 mg/implant

(3.5 mg/pellet)

In accordance with the provisions of

21 U.S.C. 811(a) of the CSA, this action

is a formal rulemaking ‘‘on the record

after opportunity for a hearing.’’ Such

proceedings are conducted pursuant to

the provisions of 5 U.S.C. 556 and 557

and, as such, are exempt from review by

the Office of Management and Budget

pursuant to Executive Order (E.O.)

12866, section 3(d)(1).

The Deputy Assistant Administrator,

Office of Diversion Control, in

accordance with the Regulatory

Flexibility Act [5 U.S.C. 605(b)], has

reviewed this rule and by approving it

certifies that it will not have a

significant economic impact on a

substantial number of small-business

entities. The inclusion of a product in

21 CFR 1308.26 relieves persons who

handle the product in the course of

legitimate business from the

requirements imposed by the CSA.

This rule will not result in the

expenditure by State, local and tribal

governments, in the aggregate, or by the

private sector, of $100,000,000 or more

in any one year, and it will not

significantly or uniquely affect small

governments. Therefore, no actions were

deemed necessary under provisions of

the Unfunded Mandates Reform Act of

1995.

This rule is not a major rule as

defined by section 804 of the Small

Business Regulatory Enforcement

Fairness Act of 1996. This rule will not

result in an annual effect on the

economy of $100,000,000 or more; a

major increase in costs or prices; or have

significant adverse effects on

competition, employment, investment,

productivity, innovation, or on the

ability of the United States-based

companies to complete with foreignbased companies in domestic and

export markets.

This rule will not have substantial

direct effects on the States, on the

relationship between the national

government and the States, or on the

distribution of power and

responsibilities among the various

levels of government. Therefore, in

accordance with E.O. 12612, it is

determined that this rule will not have

sufficient federalism implications to

warrant the preparation of a Federalism

Assessment.

Dated: September 8, 1997.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 97–25973 Filed 10–2–97; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

21 CFR Part 1308

[DEA No. 160F]

Schedules of Controlled Substances:

Exempt Anabolic Steroid Products

AGENCY: Drug Enforcement

Administration, Department of Justice.

ACTION: Final rule.

SUMMARY: The interim rule (62 FR

29288, May 30, 1997) which identified

ten anabolic steroid products as being

exempt from certain regulatory

provisions of the Controlled Substances

Act (CSA) (21 U.S.C. 801 et seq.) is

adopted without change.

DATES: Effective Date: October 3, 1997.

FOR FURTHER INFORMATION CONTACT:

Frank L. Sapienza, Chief, Drug and

Chemical Evaluation Section, 202–307–

7183.

SUPPLEMENTARY INFORMATION: The

Acting Deputy Assistant Administrator,

Office of Diversion Control, Drug

Enforcement Administration (DEA),

published in the Federal Register, an

interim rule which identified ten

products as being exempt anabolic

steroid products (62 FR 29288, May 30,

1997). Comments were requested, none

were received.

Therefore, pursuant to the authority

delegated to the Administrator of the

DEA pursuant to 21 U.S.C. 871(a) and

28 CFR 0.100 and redelegated to the

Deputy Assistant Administrator of the

Drug Enforcement Administration

Office of Diversion Control, pursuant to

28 CFR 0.104, appendix to subpart R,

section 7(g)9, the Deputy Assistant

Administrator of the Office of Diversion

Control, hereby adopts as a final rule,

without change, the interim rule

amending 21 CFR 1308.34 which was

published at 62 FR 29288 on May 30,

1997.

The anabolic steroid containing

compounds, mixtures, or preparations

which are described in 21 CFR 1308.34

are as follows: